Isto Biologics was formed in 2016 when St. Louis-based Isto Technologies and Arteriocyte Medical Systems Inc. of Hopkinton, Massachusetts, joined forces under the Isto Holdings umbrella. Isto Biologics is focused on offering evidence-based solutions for bone regeneration and cell therapy to help improve patient outcomes. The company’s best-in-class product offerings include Arteriocyte’s market-leading Magellan® Autologous Platelet Separator and Isto’s bone-growth and cell-therapy products including InQu® Bone Graft Extender & Substitute; Influx®, a natural bone-graft material; and CellPoint®, a concentrated bone marrow aspirate system.
Location: United States, Massachusetts, Hopkinton
Employees: 51-200
Founded date: 1997
Investors 3
| Date | Name | Website |
| - | Thompson S... | tscp.com |
| - | Sheridan | sheridancp... |
| 23.09.2025 | Keensight ... | keensightc... |
Mentions in press and media 3
| Date | Title | Description |
| 17.09.2025 | Keensight Capital acquires majority stake in Isto Biologics, a leading orthobiologics player, from Thompson Street Capital Partners | - |
| 04.09.2025 | Synchrocare and Isto Biologics Partner to Expand Access to Advanced Regenerative Technologies | We’re pleased to partner with Isto to expand access to their biologics and to support the clinicians providing advanced patient care.” — Reza Yazdian, J.D.OH, UNITED STATES, September 4, 2025 /EINPresswire.com/ -- In a move that reflects co... |
| - | Thompson Street Capital Partners Acquires ISTO Biologics’ Commercial Business | ST. LOUIS (June 3, 2016) – Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis with $1.5 billion of assets under management, announced today that it has acquired the commercial operations of ISTO Biologics (IST... |